Allergan Aesthetics reports improved facial satisfaction in GLP-1 users after aesthetic treatments

Allergan Aesthetics has reported new Phase IV findings showing improvements in facial appearance and skin quality among adults taking GLP-1 medications following aesthetic treatment.

The results come from the HARMONY IN DIVERSITY and HALO studies and were presented at the 2026 American Society for Dermatologic Surgery Annual Meeting.

Both studies evaluated aesthetic treatments in adults taking stable doses of GLP-1 medications, a population that may experience facial volume loss and changes in skin quality during weight loss.

In the medical weight loss cohort of HARMONY IN DIVERSITY, 30 adults received hyaluronic acid injectables, onabotulinumtoxinA and a study-specified skincare regimen.

Participants recorded a statistically significant 42.4-point mean improvement in FACE-Q Satisfaction With Facial Appearance from baseline to 30 days after treatment with onabotulinumtoxinA.

Statistically significant improvements were also observed in skin quality, psychological function and social function.

Most treatment-related adverse events were mild and non-serious and resolved without intervention, with no evidence of distant spread of toxin.

The HALO study separately assessed hyaluronic acid injectable treatment across the face in adults taking GLP-1 medications.

In an interim analysis of 25 participants, FACE-Q Satisfaction With Facial Appearance improved by an average of 39.6 points from baseline to month three.

Around 95.7% of participants said they were satisfied or very satisfied that they continued to look like themselves, while 82.6% were satisfied or very satisfied with how natural they looked.

A further 88% were satisfied with how natural their skin appeared.

Most treatment-related adverse events reported in the interim analysis were mild and non-serious.

Both studies used validated patient-reported outcome measures including FACE-Q and SKIN-Q, with higher scores representing better outcomes.

Joely Kaufman-Janette, MD, an investigator in the studies, said people taking GLP-1 medications can experience facial changes that influence self-image and social interactions.

She said research specifically focused on this population may help clinicians better understand treatment expectations and individual aesthetic concerns.

Allergan Aesthetics also presented wider research at ASDS 2026 covering multimodal facial treatment, investigational trenibotulinumtoxinE, skincare products containing fibroblast-derived exosomes and body contouring strategies.

The broader HARMONY IN DIVERSITY study enrolled 130 adults across 10 U.S. sites, including 100 participants in a general multimodal treatment cohort and 30 adults taking GLP-1 medications.

HALO is an ongoing Phase IV study evaluating HA injectables in adults taking GLP-1 therapies, with the ASDS findings representing an interim analysis of 25 of the planned 75 treated participants.

---

---

Related Topics and Keywords

AbbVie, aesthetic medicine, allergan aesthetics, ASDS 2026, BOTOX® Cosmetic, clinical research, dermatology, FACE-Q, facial aesthetics, facial volume loss, GLP-1, HALO, HARMONY IN DIVERSITY, hyaluronic acid injectables, medical weight loss, onabotulinumtoxina, patient satisfaction, pharma news, Phase IV, skin quality, SKIN-Q